$963 Million is the total value of Versant Venture Management, LLC's 12 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 27.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CRSP | Sell | CRISPR Therapeutics AG | $465,525,000 | +53.3% | 3,040,462 | -16.3% | 48.34% | -13.0% |
| NARI | New | Inari Medical, Inc. | $200,611,000 | – | 2,298,217 | +100.0% | 20.83% | – |
| ALGS | New | Aligos Therapeutics, Inc. | $91,033,000 | – | 3,292,339 | +100.0% | 9.45% | – |
| ADVM | Sell | Adverum Biotechnologies, Inc. | $54,242,000 | -24.8% | 5,003,892 | -28.6% | 5.63% | -57.3% |
| FLXN | Flexion Therapeutics, Inc. | $44,343,000 | +10.9% | 3,842,578 | 0.0% | 4.60% | -37.1% | |
| OCUL | Sell | Ocular Therapeutix, Inc. | $30,333,000 | +79.9% | 1,465,384 | -33.9% | 3.15% | +2.1% |
| CRNX | Crinetics Pharmaceuticals, Inc. | $28,652,000 | -10.0% | 2,030,616 | 0.0% | 2.98% | -48.9% | |
| AKRO | Akero Therapeutics, Inc. | $20,065,000 | -16.2% | 777,727 | 0.0% | 2.08% | -52.5% | |
| GRTS | Buy | Gritstone Oncology, Inc. | $17,536,000 | +113.3% | 4,450,638 | +43.4% | 1.82% | +21.0% |
| APRE | Sell | Aprea Therapeutics, Inc. | $7,018,000 | -84.3% | 1,426,328 | -23.1% | 0.73% | -91.1% |
| CBAY | CymaBay Therapeutics, Inc. | $3,121,000 | -20.7% | 543,753 | 0.0% | 0.32% | -55.1% | |
| CLVS | Clovis Oncology, Inc. | $489,000 | -17.7% | 101,855 | 0.0% | 0.05% | -53.2% | |
| EYES | Exit | Second Sight Medical Products, Inc. | $0 | – | -561,612 | -100.0% | -0.09% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CymaBay Therapeutics, Inc. | 35 | Q2 2023 | 10.2% |
| Clovis Oncology, Inc. | 32 | Q3 2022 | 53.2% |
| CRISPR Therapeutics AG | 23 | Q3 2023 | 77.2% |
| Ocular Therapeutix, Inc. | 22 | Q4 2020 | 18.0% |
| Gritstone Oncology, Inc. | 18 | Q3 2023 | 25.4% |
| Achaogen, Inc. | 18 | Q1 2019 | 23.5% |
| Adverum Biotechnologies, Inc. | 15 | Q3 2023 | 21.0% |
| Second Sight Medical Products, Inc. | 15 | Q3 2020 | 9.0% |
| Audentes Therapeutics, Inc. | 13 | Q3 2019 | 39.6% |
| Aligos Therapeutics, Inc. | 12 | Q3 2023 | 15.7% |
View Versant Venture Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-08 |
| 13F-HR | 2023-11-03 |
| 13F-HR | 2023-08-09 |
| 13F-HR | 2023-05-11 |
| 144 | 2023-04-20 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-11 |
| 13F-HR | 2022-05-10 |
| 13F-HR | 2022-02-11 |
View Versant Venture Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.